Accumulation of DNA damage in the first 1000 days may increase risk of accelerated ageing and degenerative diseases in adult life such as cancers. The extent of DNA damage in infants and the correlation of maternal factors during pregnancy with neonate birth outcomes and DNA damage is not known in infants born in Australia. Therefore, we performed a prospective cohort study to collect data on DNA damage in lymphocytes of Australian infants (aged 0, 3 and 6 months), using the cytokinesis block micronucleus cytome (CBMN-Cyt) assay. The study also explored correlation of CBMN-Cyt biomarkers with infant birth outcomes and maternal anthropometric and lifestyle variables. Peripheral blood lymphocytes were isolated from the infants at birth (cord blood) (n = 82), 3 months (n = 64) and 6 months (n = 53) after birth. DNA damage biomarkers measured ex vivo in binucleated lymphocytes (BNC) included: micronuclei (MN), nucleoplasmic bridges (NPB) and nuclear buds (NBUD). Apoptotic and necrotic lymphocytes were also scored and nuclear division index (NDI) was measured using the frequency of mono-, bi-and multinucleated lymphocyte. MN and NBUD were also scored in mononucleated lymphocytes (MNC). The mean (± SD) frequency of MN, NPB and NBUD in BNCs at birth was 2.0 (± 1.2), 5.8 (± 3.7) and 11.1 (± 5.7) per 1000 BNC, respectively, and tended to decrease significantly at 3 months (P < 0.01, P < 0.0001, P < 0.001, respectively) and 6 months (P < 0.05, P < 0.0001, P < 0.0001, respectively) after birth relative to cord blood when compared with the same cohort of infants (n = 48 at birth, 48 at 3 months and 39 at 6 months). None of the CBMN cytome biomarkers measured at birth was associated with maternal smoking status, alcohol and folic acid intake during pregnancy. The mean gestation age correlated positively with MN (r = 0.38, P = 0.006), NPB (r = 0.30, P = 0.03) and negatively with NDI (r = −0.29, P = 0.03). Infant birth weight associated positively with MN, NPB and NBUD in cord blood (r = 0.24, P = 0.08; r = 0.32, P = 0.02; r = 0.28, P = 0.04, respectively), birth length associated positively with NPB (r = 0.32, P = 0.02) and NBUD (r = 0.27, P = 0.04) while head circumference associated negatively with apoptotic cells (r = −0.27, P = 0.06). APGAR score at 1 and 5 min after birth associated positively with NDI at birth (r = 0.3, P = 0.05, r = 0.28, P = 0.06, respectively). Mother's weight and body mass index 356 M. D. Singh et al., 2017, Vol. 32, No. 3 (BMI) recorded at the time of recruitment associated positively with NPB (r = 0.38, P = 0.006, r = 0.32, P = 0.02, respectively) and negatively with APGAR score at 5 min (r = −0.25, P = 0.07). The significant positive associations of infant birth weight and length and maternal BMI with CBMN-Cyt biomarkers suggest the possibility of a genotoxic effect of metabolic processes that promote excessive growth and high BMI.
Introduction
In Australia, the incidence of childhood cancer is estimated to increase but the causes remain uncertain (1) . Insults to the genome in the perinatal period are likely to contribute to carcinogenesis and may be more important relative to other life stages because of the higher probability that mutated and genomically unstable cells could populate the rapidly growing tissues of an infant (2) (3) (4) (5) . Mutations of the genome may have particularly adverse consequences in early life, including developmental defects and immune system dysfunction (4, 5) and an increase in the risk for early onset of degenerative diseases (6, 7) . Detection and monitoring of DNA damage in human tissues at the earliest possible phase of life may enable timely intervention to prevent the further accumulation of cellular DNA lesions and their potential manifestation into chronic diseases, such as cancer, at a later stage of life (8) . Among all the genome damage biomarkers, micronuclei (MN frequency) is one of the most sensitive biomarkers used in the bio-monitoring of cord blood, newborns and children (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) because of its potential to detect clastogenic and aneugenic effects in the human genome (18) . The Human MicroNucleus project compiled prospective data on MN frequency assessed in lymphocytes of 6718 individuals (who were free of cancer at the time of testing) from 10 countries with cancer incidence and found a significant increase of incidence of cancers in medium [relative risk (RR) 1.84; 95% CI: 1.28-2.66] and high MN frequency groups (RR 1.53; 95% CI: 1.04-2.25) (8, 19, 20) thereby showing that MN is a biomarker for early genetic effect and is predictive of cancer risk.
DNA damage sustained during both the perinatal period and infancy may also reflect the epigenomic impact of maternal diet, life-style and genotoxin exposures (21) (22) (23) (24) (25) (26) because gene expression related to DNA damage and immune response among children is observed to correlate with MN as a consequence of exposure to environmental pollutants (24, 25, 27, 28) . Additionally, there is accumulating evidence that infant's birth weight and gain in weight during childhood is affected by maternal pre-pregnancy weight (29) and ambient exposures to PM 2.5 air pollutant (30, 31) , suggesting the possibility of an association of MN frequency in maternal and neonates blood with peri and postnatal maternal diet and lifestyle factors (32, 33) . The available data for CBMN-Cyt biomarkers, primarily MN frequency measured in binucleated lymphocytes (BNCs) in cord blood among various populations has been summarized in Figure 1 .
MN frequency is measured utilizing the cytokinesis block micronucleus-cytome (CBMN-Cyt) assay in peripheral blood lymphocytes (PBL) and when used in the 'cytome' mode is one of the most comprehensive and best validated methods to measure chromosomal DNA damage, cytostasis and cytoxicity (44) . In this assay, genome damage is measured by scoring: micronuclei (MN): biomarker of both chromosome breakage and/or loss; nucleoplasmic bridges (NPB): a biomarker of DNA mis-repair and/or telomere end fusions and nuclear buds (NBUD): a biomarker of gene amplification and / or the removal of unresolved DNA repair complexes (45, 46) . DNA damage biomarkers expressed ex vivo (MN, NPB, NBUD) are measured in once-divided binucleated lymphocyte cells (BNC, that are accumulated by blocking cytokinesis with cytochalasin-B) because only cells that complete nuclear division can express molecular lesions in DNA and in the mitotic machinery that lead to MN, NPB and NBUD formation. Genome damage already expressed in vivo as MN and NBUD is measured in mononucleated lymphocyte cells (MNC) that fail to divide in vitro in the CBMN-Cyt assay (34, 47) .
To date, there have been no published data on baseline DNA damage biomarkers in infants born in Australia during first 6 months after birth. A prospective study: the 'Diet and DNA Damage in Infants' (DADHI) study was therefore designed with the primary aim of collecting comprehensive data on genome integrity of South Australian infants (aged 0-6 months), utilizing the CBMNCyt assay. A secondary objective was to test whether CBMN-Cyt assay biomarkers changed with time during the first 6 months of life and whether there is any correlation among various genome damage biomarkers. Also, the associations between CBMN-cytome assay biomarkers with maternal or infant characteristics [maternal body mass index (BMI), smoking status, folic acid intake, post-partum diet; birth weight, birth length, head circumference, gestational age and APGAR scores; infant feeding] were examined.
Materials and methods

Recruitment of participants
The DADHI prospective cohort study was conducted on healthy pregnant women and on their neonatal offspring. Pregnant women, attending the antenatal clinic at the Women's and Children Hospital (WCH) in Adelaide, South Australia, and identified as being at low risk of pregnancy complications were approached to participate in the study. Pre-determined inclusion criteria were a second viable pregnancy (naturally conceived) and having no more than two previous first trimester losses. Women with multiple and/or IVF pregnancy, or with any disease or complication (including hypertension, types I and II diabetes mellitus, epilepsy, asthma, anaemia, inflammatory bowel syndrome, renal, liver or thyroid problems) or with a BMI ≥ 35 kg/m 2 were excluded from the study. Infants born prematurely were excluded from the study. All eligible women were informed about the study aims and requirements using a detailed information sheet, before being asked to give informed and signed consent at between 8 and 16 weeks gestation. The study was approved by the Human Experimentation Ethics Committee of the Commonwealth Scientific and Industrial Research Organization (CSIRO) and the Human Research Ethics committee of the WCH, Adelaide. Blood samples were collected at birth (cord blood, n = 87), at 3 months (heel prick, n = 69) and 6 months (heel prick, n = 55) after birth from the infant. The consort diagram for detailed information on recruitment of participants and their completion of the protocol is presented in Figure 2 .
General health and food frequency questionnaire
A general health questionnaire was administered to participating women at between 16 and 28 weeks gestation to collect detailed information about the mother's anthropometric variables, medical and family history, lifestyle habits such as smoking, dose and duration of folic acid supplementation and other supplements and any medicines consumed during the pregnancy period. Mother's weight at recruitment was recorded using a digital balance accurate to within 100 g, and height was determined using a stadiometer accurate to within 1 cm of overall height. BMI was then calculated using the formula weight (kg)/height (m) 2 . Type of labour and delivery (Caesarean/ induced, normal/spontaneous) and any complications during labour was also recorded. A Food Frequency Questionnaire (FFQ) (The Cancer Council, Victoria) was administered at 3 and 6 months postpartum to collect information about the mother's intake of macro and micronutrients (48) . Details regarding infant's birth weight, height, head circumference, APGAR score at 1 and 5 minutes post birth, gender and gestation age were also recorded. APGAR score was devised by Dr Virginia Apgar with the aim to standardize the assessment of newborns utilizing five signs: heart rate, respiratory effort, muscle tone, reflex irritability and colour (49) . A rating of zero, one or two, is given to each sign depending on its presence or absence. A final aggregate score of 10 indicates the best possible infant birth outcomes (50) .
Blood collection
Approximately 20 ml of cord blood was collected immediately after birth into two 9 ml sterile Lithium Heparin coated collection containers (green top; Greiner Vacuette 2 ml Cat.No. 454089). The tubes were kept at 4°C before being transported to the CSIRO Nutrigenomics laboratory in a lab top cooler within 4-6 h of collection. The cord blood was kept at room temperature (18-22°C) and was prepared for the CBMN-Cyt assay within 8 h of collection (51) . At the 3 and 6 month time points, 1 ml of infant blood was collected in a Vacuette® Lith/Hep coated tube by an experienced nurse at CSIRO clinic into a 1-ml mini vial from a heel prick using the tenderfoot method (52) and was stored in a labtop cooler (Nalgene 0°C labtop cooler 3 × 4 tubes 17 mm, Lot: 7111573010) at 18-22°C and the CBMN-Cyt assay was performed within 8 h of collection.
CBMN-Cyt assay
The whole blood CBMN-Cyt assay was conducted in duplicate on all collected samples (cord blood, 3 and 6 month bloods) (44) .
Preparation of reagents
Ficoll-Paque 100 ml sterile liquid (Amersham Pharmacia Biotech, Sweden, cat no. 17144002). This product is stable if bottle remains unopened, however is susceptible to deterioration on exposure to air for prolonged duration. Hence, the bottle is dated on opening; the solution is extracted with the use of sterile needle and syringe without opening the seal and minimum amounts (100 ml) of solution is extracted for a single use.
Hanks Balanced Salt solution (HBSS)
Sterile with calcium and magnesium without phenol red (Trace Scientific, Melbourne, Australia, Cat no. 111010500-V); stored at 4°C but use at room temperature.
RPMI 1640 medium without l-Glutamine 100 ml sterile liquid (Sigma, R0883, Australia). Store at 4°C. Use at 37°C when preparing cultures.
Fetal bovine serum (FBS) 100 ml, sterile FBS (Trace Scientific, Melbourne, Australia, cat no 15010-0100V) is stored at −20°C. Thaw in a 37°C water bath before adding to the culture medium. The thawed solution is stable for 4 weeks. Repeated thawing and refreezing were avoided. 
L-Glutamine
200 mM sterile solution (Sigma, Sydney, Australia, cat no. G7513); stored in 1 ml aliquots at −20°C for up to 2 years. The solution was thawed at room temperature before adding to the culture medium.
Sodium pyruvate 100 mM sterile solution (Sigma, Sydney, Australia, cat no. S8636), stored at −20°C in 1 ml aliquots for up to 2 years. The solution was thawed at room temperature before adding to the culture medium.
Culture medium
[RPMI, 10% FBS, 1% sodium pyruvate (100 mM) and 1% l-glutamine (200 mM)]. 20 ml of culture medium was prepared using 17.6 ml RPMI, 2 ml FBS, 200 µl Glutamine and 200 µl sodium pyruvate. The culture medium was prepared in a sterile tissue culture grade plastic bottles. It may be stored at 4°C for up to 1 week. Before use, the media was pre-warmed at 37°C in a humidified incubator with a 5% CO 2 atmosphere.
DMSO
Sterile filtered solution of DMSO (Sigma, D2650, Australia) was stored at room temperature (20°C).
Cytochalasin-B
(Cyto-B, Sigma, C6762, Australia): Five milligrams of solid Cyto-B was dissolved in 8.33 ml DMSO to give a Cyt-B solution 600 µg/ml. This stock Cyto B was stored at −20°C in a vial for 12 months. On the day of assay, 100 µl of the stock Cyto B was thawed, and 900 µl of culture medium was aseptically added at room temperature to the vial to obtain a 1000 µl solution of 60 µg/ml. This cytotoxic agent is a possible teratogen and hence was prepared in a Cyto guard cabinet and for precaution personal protective clothing including Tyvek gown, double nitrile gloves and safety glasses were used.
Phytohemagglutinin
(PHA, Murex Biotech, Dartford, UK, Cat no 8e27-01): 45 mg freeze dried extract of PHA was dissolved in 20 ml sterile isotonic saline to give a concentration of 22.5 mg/ml. This stock PHA could be stored for 4 weeks only. On the day of assay, 100 µl of stock PHA was diluted with 900 µl of culture media to get a working solution of 2.25 mg/ml. PHA is required to stimulate lymphocytes to perform DNA replication and nuclear division. PHA predominantly stimulates T lymphocytes (53) .
Diff Quik fixative and cell stain set (Lab Aids, Narrabeen, Australia).
DePeX
Mounting medium (BDH laboratory, Poole, UK).
The CBMN-Cyt protocol
A schematic representation of the protocol is shown in Figure 3 . Duplicate whole blood lymphocyte culture for each blood sample from a participant was prepared. On days 0, 100 µl of heparinised whole blood was cultured in 810 µl medium. The mitogenic activity in lymphocytes was initiated by adding 90 µl PHA solution to give a final concentration of 202.5 µg/ml. The time of PHA addition was recorded. The culture tube was incubated at 37°C with loosened lids in a humidified atmosphere containing 5% carbon dioxide for 44 h. At 44 h, the culture tubes were carefully removed from the incubator and 100 µl of cyto-B solution was gently mixed into the cultures. The culture tubes were then returned to the incubator for a further 24 h. At 68 h, cultures were removed from the incubator, and the cells were mixed gently. The cell suspension was underlaid with 400 µl of Ficoll-Paque (Amersham Pharmacia Biotech, Sweden, cat no. 17144002) in a TV10 tube (Techno Plas, S9716VSU, Australia) using a ratio of 1 (Ficoll):3 (cell suspension) without disturbing the interface. The tube containing culture suspensions overlaid on Ficoll was then centrifuged once at 400 g for 30 min at 18-20°C to separate the lymphocytes. Using a pipette with a 200 µl clear plugged tip, the 'buffy' lymphocyte layer at the interface of the Ficoll Paque and medium was removed carefully avoiding uptake of Ficoll. The lymphocyte suspension was washed in three times its volume of Hanks balanced salt solution (Hanks HBSS, Trace Scientific, Melbourne, Australia, Cat no. 111010500-V) by gently pipetting in 1320 µl HBSS solution and then centrifuging at 180 g for 10 min at room temperature to remove any residual Ficoll and cell debris. The supernatant was gently removed, leaving approximately 200 µl suspension. Subsequently, 15 µl dimethyl sulfoxide (DMSO 7.5% v/v of cell suspension Sigma, Sydney, Australia) was added to prevent clumping and to optimize visualization of cytoplasmic boundaries of lymphocytes. This was followed by harvesting of lymphocytes by cytocentrifugation onto cleaned slides. Microscope slides were cleaned by washing in absolute ethanol and then allowed to dry for 10 min. The slides were then labelled and assembled with a filter card onto a cytocentrifuge cup utilizing a slide holder. The combined slide, filter card and cytocentrifuge cup were arranged as per manufacturer's instruction and spun in a cytocentrifuge (Model Cytospin 3, Shandon Southern Products, Cheshire, UK).
One hundred microliters of lymphocytes suspension was added to the cytospin cup corresponding to the numbered slide in the rotor and spun at 600 rpm for 5 min. A spot was obtained at the end of centrifugation. The card and the slide were inverted and the above process repeated in order to obtain a second spot. The slides were air dried in a biohazard hood for 10 min followed by fixing in Diff Quick fixative (Lab Aids, Narrabeen, Australia) for 10 min. Then the slides were transferred directly into Diff Quick stain: 10 dips in the orange stain followed by 5 dips in the blue stain. The extra stain was washed off with tap water and slides were left to air dry for 10 min. The slides were finally cover slipped using DePeX mounting medium (BDH laboratory, Poole, UK) in a fume-hood. A slide with two stained cytospin cell spots was thus prepared from each of the duplicate cultures was thus prepared. A conventional light microscope (Model Leica DMLB2: Leica Microsystem, Wetzlar, Germany) was used to examine the lymphocytes at 1000× magnification. For each scoring analysis two scorers (MH and TA) individually determined cytostatic and cytotoxic events by scoring 500 cells including mono-, bi-, multinucleated lymphocyte, necrotic and apoptotic lymphocyte according to previously published classification criteria (44) . This allowed calculation of nuclear division index (NDI). The NDI provides a measure of the proliferative status of the viable cell fraction and thus indicates mitogenic response in lymphocytes (44) .
The formula for calculating NDI is as follows (54) .
where M1-M4 represent the number of lymphocytes with 1-4 nuclei N is the total number of viable lymphocytes scored (excluding necrotic and apoptotic lymphocytes).
Both the scorers (MH and TA) independently counted the CBMN-Cyt assay genome damage biomarkers (MN, NPB, NBUDs) in 1000 BNCs from each duplicate culture tubes to give an overall total for each biomarker per 4000 BNCs scored per sample. The results were then averaged and presented for every 1000 BNC. A third scorer (MD) independently counted all MNCs per spot in a slide, and DNA damage biomarkers (MN and NBUDs) in MNCs, using criteria previously described (55) . An average of 500 MNCs were scored for MN and NBUDs in each duplicate culture. The results in MNCs were expressed as MN and NBUD per 100 MNCs per subject. The HUMN scoring criteria recommends that the MN frequency be determined in a minimum of 1000 cells (55) but in 40% of our slides, there were insufficient MNC to score 1000 cells which is why the frequency of MN and NBUD is expressed per 100 MNCs.
Power calculations
Based on previously published data on 408 newborns (35) (36) (37) 56) , the expected mean [standard deviation (SD)] of micronucleus frequency measured in lymphocytes using the CBMN cytome assay is 1.20 (1.02). Using the SD value of 1.02, the study was powered to detect differences in micronucleus frequency between two groups ranging between 0.41 and 0.58 at 80% power and P < 0.05 (twotailed) depending on the number of subjects per group (50-100) (and is shown in Supplementary Table I, available at Mutagenesis Online).
Statistical analysis
The mean (± SD) for CBMN biomarkers was calculated for all the infants (even if they did not complete the study till 6 months) from whom PBLs were collected at birth (cord blood), 3 and 6 months. The data for each CBMN-Cyt assay biomarker was first analysed to test whether the distribution was Gaussian by using the D'Agostino-Pearson omnibus normality test which determined the choice of subsequent tests (parametric or non-parametric). Degrees of association between continuous variables (for the same cohort of infants from whom blood was collected at all three time points) were evaluated by correlation analysis. Pearson correlation coefficients were calculated for Gaussian distributed data. Correlation analysis for non-Gaussian distributed data was performed using the Spearman rank test. Differences between the CBMN-Cyt biomarkers at 0, 3 and 6 months were assessed using analysis of variance (ANOVA) for repeated measures. Analysed data are presented as mean ± SD. Differences with P < 0.1 (two-tailed) were considered statistically significant. For multiple comparisons of group at three time points, post hoc t-test for linear trend' and 'Tukey's test' were also conducted. The effect of lifestyle and supplementation variables recorded for mothers during pregnancy (smoking, BMI, alcohol and folic acid intake) on CBMN-Cyt biomarkers measured in the cord blood were also assessed using 'student t test' for normal distributed data and 'Mann-Whitney's t test' for non-Gaussian data. Graph Pad Prism version 6.04 for Windows (Graph Pad Inc., San Diego, CA, USA) and SPSS 22.0 (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) were used for all statistical analyses.
Results
General demographics of the cohort
The mean ± (SD) data for general demographic characteristics for mother-infant cohort is presented in Table 1 . 4.5% of the maternal cohort reported smoking during pregnancy, 59.6% reported alcohol consumption during pregnancy, one subject was on a vegan diet and 94% reported taking folic acid supplements (400 µg/day). The mean (± SD) birth weight of infants (n = 82) was 3463 (± 421) g. At birth, mean weight of male and female infants was 3656 (± 341) and 3245 (± 398) kg, birth length was 51.0 (± 1.6) and 50.0 (± 3.8) cm, head circumference was 35.9 (± 3.3) and 34.3 (± 1.3) cm, respectively. The mean (± SD) infant weight at 3 months [n = 64, mean (± SD) age 12.7 (± 1.01) weeks] was 6207 (± 763) g and male and female infants weighed 6490 (± 677) and 5968 (± 765) g, respectively]. At 6 months, [n = 53, mean (± SD) age 23.7 (± 1.20) weeks] the mean (± SD) weight was 7896 (± 922) g and male and female infants weighed 7820 (± 1696) and 7667 (± 838), respectively.
Mean CBMN-Cyt biomarkers measured in the cohort at birth, 3 and 6 months
The mean and standard deviation for each CBMN-Cyt biomarker at birth, 3 and 6 months for all the infants (even if they did not complete the study till 6 months) is presented in Table 2 . At birth mean (± SD) for frequency of MN, NPB and NBUD measured in BNCs was 2.0 (± 1.2), 5.8 (± 3.7) and 11.1 (± 5.7), respectively. The frequency of apoptotic and necrotic lymphocytes was 6.6 (± 4.1) and 35.9 (± 12.2), respectively. Mean (± SD) for NDI was 1.5 (± 0.16) and mean frequency of MN and NBUD in MNCs was 0.19 (± 0.21) and 1.0 (± 0.80), respectively. At 3 months, mean (± SD) for MN, NPB and NBUD in BNCs was 1.6 (± 1.1), 3.1 (± 1.6) and 7.9 (± 3.8), respectively. The mean frequency of apoptotic and necrotic lymphocyte was 7.1 (± 2.9) and 29.7 (± 7.9), respectively. The mean (± SD) for NDI was 1.7 (± 0.14), and for MN and NBUD in MNCs it was 0.16 (± 0.15) and 0.64 (± 0.42), respectively. At 6 months, mean (± SD) for MN, NPB and NBUD in BNCs was 1.7 (± 1.2), 2.7 (± 2.5) and 7.3 (± 3.5), respectively.
Gender differences for birth outcomes and CBMN-Cyt biomarkers
The birth weight, length and head circumference of the male infants was greater than that of the female infants (P < 0.0001, P = 0.0003, P = 0.001, respectively). Male infants had higher NBUD BNC and NBUD MNC than female (P = 0.08 and P = 0.07, respectively). At 3 months, male infants were heavier by 8% (P = 0.03) and had higher MNMNC than female cohort (P = 0.05). At 6 months, no gender difference was observed for CBMN-cyt biomarkers ( Table 2) .
Correlation between infants' birth outcomes and CBMN-Cyt biomarkers measured in cord blood
The summary of associations between infants' birth outcomes and DNA damage biomarkers is presented in Table 3 . Gestation age for infants at birth correlated positively with MN (r = 0.38, P = 0.006 and NPB (r = 0.3, P = 0.03) in BNCs but no association was observed with other cytome biomarkers, except for an inverse trend with NDI (r = −0.29, P = 0.03). Infant birth weight was associated positively with MN, NPB and NBUD in BNCs (r = 0.24, P = 0.08, r = 0.32, P = 0.02, r = 0.28, P = 0.04, respectively). Infant birth length was positively associated NPB and NBUD in BNCs (r = 0.32, P = 0.02, r = 0.27, P = 0.04). Infant head circumference was observed to be negatively associated with apoptosis (r = −0.27, P = 0.06). APGAR score at 1 and 5 min was positively associated with NDI (r = 0.3, P = 0.05, r = 0.28, P = 0.06, respectively) while with NPB it was observed to have a negative association (r = −0.26, P = 0.09).
Correlation between maternal lifestyle and anthropometric factors with infant birth outcomes and CBMN-Cyt biomarkers measured in cord blood
The study did not find correlation between mothers' lifestyle characteristics (smoking, alcohol intake, folic acid consumption) and CBMN-Cyt biomarkers measured in cord blood (Results are presented as Supplementary Tables II-V, available at Mutagenesis Online). Mothers' weight and BMI at recruitment were positively associated with NPB BNC in cord blood (r = 0.38, P = 0.006, r = 0.32, P = 0.02, respectively). Mother's age was negatively correlated with frequency of apoptotic lymphocytes (r = −0.25, P = 0.07) ( Table 4 ). Mother's height was positively associated with infant birth weight (r = 0.21, P = 0.09) and BMI was negatively correlated with APGAR score at 5 min [r = −0.25, P = 0.07)] (Table 5 ). Gestation age was also positively associated with infant birth weight (r = 0.33, P = 0.005) and length (r = 0.26, P = 0.03) (The results are shown in Supplementary Table VI, available at Mutagenesis Online).
Differences among CBMN-Cyt biomarkers in infants' lymphocytes at birth and at 3 and 6 months after birth
In order to test the hypothesis that the age of the infant has an effect on the genome instability biomarkers measured in lymphocytes, repeat measures ANOVA (one way) was performed (Table 6) . For this analysis, only data for those infants from whom blood was collected at all three time points (birth, 3 and 6 months) was analysed. There were significant differences between all the CBMN-Cyt biomarkers at three time points except for biomarkers measured in MNC. MN, NPB and NBUD in BNCs decreased significantly by 28.7, 52.6 and 34.9%, respectively, at 3 months and by 22.6, 58 and 35.9%, respectively, at 6 months relative to cord blood. NDI and apoptotic lymphocyte frequency increased significantly by 16.2 and 42.8%, respectively, at 3 months and 14.8 and 30%, respectively, at 6 months relative to cord blood. To further assess the nature and trend of differences, post hoc test for linear trend was analysed which showed significant decline in MN, NPB, NBUD in BNCs and necrosis while significant increase in NDI and apoptotic lymphocyte ( Figure 4 ) but no change in MN and NBUD in MNCs ( Figure 5 ).
Correlation between CBMN-Cyt biomarkers in infants at birth and at 3 and 6 months
Correlation analysis was conducted for the same cohort of infants at birth (n = 48), 3 months (n = 48) and 6 months (n = 39). A significant positive correlation was observed for NBUD BNC at birth and at 3 months (r = 0.45, P = 0.001) ( Table 7) . A similar positive relationship was evident for NPB in BNCs at birth and at 3 months (r = 0.47, P = 0.0006) but there was no correlation at birth and 3 months for MN BNC (Figure 6 ). The frequency of apoptotic and necrotic lymphocytes assessed at birth did not correlate with their frequency measured at 3 months, however NDI at birth and 3 months were positively correlated (r = 0.35, P = 0.01) with each other. NPB BNC at birth correlated significantly with those measured at 6 months. (r = 0.36, P = 0.02). Among all CBMN-Cyt biomarkers measured at 3 months, MN, NPB and NBUD in BNCs correlated positively with those measured at 6 months (r = 0.35, P = 0.01, r = 0.29, P = 0.03 and r = 0.24, P = 0.08, respectively). NDI at 3 and 6 months also positively correlated with each other (r = 0.24, P = 0.08) NBUD measured in MNC at 3 and 6 months were positively associated with each other (r = 0.26, P = 0.06).
Correlation between NDI with genome instability biomarkers at birth, 3 and 6 months
Because DNA damage in lymphocytes may impair cell proliferation and immune response, we investigated the correlation between NDI and MN, NPB and NBUD in BNC. At birth, NDI was negatively correlated with NPB BNC (r = −0.45, P < 0.0001) and positively with necrotic lymphocytes (r = 0.27, P = 0.01) (Supplementary Table VIIa, available at Mutagenesis Online). At 3 months, an inverse correlation was observed between NDI and NPB (r = −0.31, P = 0.01) and NBUD (r = −0.36, P = 0.002) measured in BNCs (Supplementary Table VIIb, available at Mutagenesis Online) and NBUD in MNCs (r = −0.22, P = 0.08). At 6 months, NDI showed significant negative association with MN, NPB and NBUD in BNCs (r = −0.24, P = 0.08, r = −0.22, P = 0.1, r = −0.31, P = 0.02) (Supplementary Table VIIc, available at Mutagenesis Online). Table 2 . Mean (± SD) CBMN-Cyt biomarkers and gender differences measured at birth, 3 and 6 months in male and female infants CBMN-Cyt biomarkers CBMN-Cyt biomarkers Table 8 ).
Discussion
The rise in incidences of cancers, cardiometabolic diseases and other inflammatory conditions such as childhood asthma is a major public health concern (1,57) warranting innovative strategies to understand Each infant birth outcome was tested for Gaussian distribution and then Pearson 'r' (parametric test for normal distribution data) and Spearman 'r' was calculated (non-parametric test for non-Gaussian distribution).
Significant at *P ≤ 0.1 (All P value are two-tailed). Each DNA damage biomarker was tested for Gaussian distribution and then Pearson 'r' (parametric test for normal distribution data) and Spearman 'r' was calculated (non-parametric test for non-Gaussian distribution). MN, NPB and NBUD presented per 1000 BNC, apoptotic and necrotic lymphocytes are presented per 500 cells, MN and NBUD presented per 100 MNCs.
Significant at ***P ≤ 0.01; **P ≤ 0.05, *P ≤ 0.1 (All P value are two-tailed). Each DNA damage biomarker was tested for Gaussian distribution and then Pearson 'r' (parametric test for normal distribution data) and Spearman 'r' was calculated (non-parametric test for non-Gaussian distribution). MN: micronuclei; BNC: Binucleated cells; NPB: Nucleoplasmic bridge; NBUD: Nuclear buds; MNC: mononucleated cells, MN, NPB and NBUD presented per 1000 BNC, apoptotic and necrotic cells are presented per 500 cells, MN and NBUD presented per 100 MNC. ***Significant at P ≤ 0.01; **P ≤ 0.05, *P ≤ 0.1 (All P value are two-tailed). ANOVA for repeat measures was performed to compare each biomarker for the same cohort of infants at birth, 3 and 6 months. Post hoc test for linear trend was significant for MN, NPB and NBUD in BNCs, NDI, apoptotic and necrotic cells but not for MN and NBUD in MNCs. Tukey's multiple comparison tests showed significant differences at birth and 3 months and birth and 6 months for all biomarkers except for those measured in MNCs. No significant difference was observed between biomarkers assessed at 3 and 6 months (These results are also presented in Figures 4 and 5) .
MN, NPB and NBUD are presented per 1000 BNCs, apoptotic and necrotic lymphocytes are presented per 500 cells, MN and NBUD are presented per 100 MNCs. genetic and epigenetic modulations of DNA integrity and stability by changing environmental factors (26) and to detect any adverse clinical manifestation at the earliest phase of life. The results presented in this article provide important novel baseline data on DNA damage, cell death and DNA replication capacity in infants at birth and the first 6 months after birth in Australia and the association of these biomarkers with maternal obesity, birth size and birth outcomes.
CBMN-Cyt biomarkers in South Australian infants at 0, 3 and 6 months
The baseline frequency for CBMN-Cyt markers in our cohort was not dissimilar from previous data in other studies (13, 17, 34, 36, 38) and decreased at 3 and 6 months relative to values measured in cord blood at birth. The mean (± SD) MN frequency in BNCs for our Australian cohort at birth (n = 82) was 2.0 (± 1.2) which is similar to the mean MN frequency reported for the lymphocyte in the cord blood of healthy newborns born to Mexican mothers residing in a rural agricultural locality [2.0 (± 1.5), n = 16] (13) and with results of a Greek cohort in the Newborns and Genotoxic exposure risks (NewGeneris) study [1.79 (± 1.5), n = 232] (17). The lowest mean MN frequency 0.55 (± 0.74) was observed in the British cohort (n = 143) in the NewGeneris study. Interestingly, a subgroup of the NewGeneris study; the Rhea mother-child cohort in Crete, (Greece), reported a higher lymphocyte mean MN frequency 4.51 (± 3.29) per 1000 BNCs in the cord blood of infants (n = 92) (34). Lope et al. (36) reported a mean MN frequency of 3.94 (3.57-4.33 at 95% CI) in cord blood lymphocytes of newborns (n = 110), born to healthy mothers in Spain. A meta-analysis of MN frequency based on 13 field studies in children (n = 440) (0-18 years) and a pooled analysis of individual data (n = 332) reported an overall mean of 4.48 and pooled baseline estimate of 3.27 MN per 1000 BNCs for infants (aged 0-1 years) (38) . The value for infants are higher than the data for our cohort perhaps because the meta-analysis data resulted from pooling for 51 children with a wider age range (0-1 years) and wider range of environmental and dietary exposures as they were residing in different countries, such as China (58), Brazil (39), Italy (59) and France (40) . The mean (± SD) frequency of MN in MNCs observed in cord blood in our study was 0.19 (± 0.21) per 100 MNCs. The equivalent mean value of MN per 1000 MNC assessed in our study would be 1.9 (± 2.1) which is similar to mean MN frequencies in MNCs observed in cohort from Greece 2.09 (± 1.54) (34) but higher than those reported in the NewGeneris study in cord blood from the Spanish 0.20 (± 0.45), Norwegian 0.11 (± 0.42) and Danish 0.17 (± 0.58) cohorts (17) . The difference between cohorts in MNMNC is likely to reflect variation in environmental exposure factors (26) . MN frequency is usually reported to increase in response to exposure to genotoxic pollutants (4, 11, 24, 41, 42, 60) , disease state (12, 35, 39, 43, 61) and deficiency of micronutrients especially folate, B 12 , vitamin E and iron (62) (63) (64) . Hence, differences in the frequency of MN measured in our study and the cohort from other countries may be attributed to diverse environmental factors (62, 65, 66) that may modulate MN through epigenetic mechanism (17, (24) (25) (26) (27) (28) including hypomethylation of pericentromeric DNA which leads to centromere dysfunction and failure of chromosome segregation leading to MN formation (45, 63) . Also, our current cohort included women at low risk of complications during pregnancy, of which only 4.5% reported smoking during pregnancy which may possibly account for a lower baseline MN frequency. Another reason for difference of MN values could be use of manual scoring in our study while the NewGeneris study used semi-automated image analysis system which tends to underestimate MN frequency relative to visual scoring (67) .
We observed that MN in BNCs and MNCs were correlated at birth and 3 months as well as at three and 6 months as reported in the NewGeneris Rhea mother-child cohort in Crete (r = 0.35, P < 0.001) study (37) suggesting that common factors in utero may impact MN frequency expression in vivo and ex vivo in the lymphocytes of infants.
The NPB frequency [mean (± SD)] for our cohort was 5.8 (± 3.7). The Rhea mother child cohort study reported much lower mean (± SD) values of NPB [0.12 (± 0.36) per 1000 BNCs] at birth (34) . The biomonitoring study in Spain reported that in neonatal lymphocytes, 16.4% were observed to have 1 NPB and 1.8% to have 2 NPB (36) . These data indicate a high variability in NPB frequency between cohorts that may be explained not only by differences in exposure factors but also laboratory and scorer variability in the efficiency of scoring NPBs which has been observed to be much higher for scoring NPB than scoring MN (68) .
The mean (± SD) frequency of NBUD observed in cord blood in our study was 11.1 (± 5.7) and is much higher than the values Table 7 . Correlation analysis between CBMN-Cyt biomarkers at birth and 3 months, birth and 6 months and 3 and 6 months
CBMN-Cyt biomarker
Birth and 3 months (n = 48) Birth and 6 months (n = 39) 3 and 6 months (n = 50)
'r' value 'P' (two tailed) 'r' value 'P' (two tailed) 'r' value 'P' (two tailed) Each DNA damage biomarker was tested for Gaussian distribution and then Pearson 'r' (parametric test for normal distribution data) and Spearman' 'r' was calculated (non-parametric test for non-Gaussian distribution). MN, NPB and NBUD are presented per 1000 BNC, apoptotic and necrotic lymphocytes are presented per 500 cells, MN and NBUD are presented per 100 MNCs.
Significant at ****P ≤ 0.001, ***P ≤ 0.01; **P ≤ 0.05, *P ≤ 0.1 (All P value are two-tailed). reported in a study conducted in Greece 0.27 (± 0.63) (34) . A low frequency of NBUD was reported in the Bio Madrid study in which only 7% of the newborns registered one or two buds (36) . The positive association between NBUD measured in infant lymphocytes at birth and 3 months and at 3 and 6 months and NBUD measured in BNCs and MNCs suggests the possibility that the lymphocytes observed in our study till 6 months were survivors from birth and were in the process of eliminating extra DNA material accumulated a few months earlier (69) . The appearance of all DNA damage biomarkers including MN, NPB and NBUD has been associated with low micronutrient status, such as folate deficiency (45, 70) ; hence it is important that the relationship between the micronutrient status of the infant and CBMN-Cyt biomarkers is assessed. Our study also observed a substantial decline in MN, NPB and NBUD frequency 3 months after birth but a little or no further decline at 6 months. The reason for this finding is not clear and whether it may be credited to a healthier ex vivo environment requires further investigation. It is possible that the lymphocytes measured in cord blood differ from matured lymphocytes collected from infants at 3 and 6 months (71) with respect to T cell subtypes and proportion of each subtypes (72,73) which was not assessed in our manual scoring process. Further, the total T lymphocytes, CD4/CD8 (74) and Th1/Th2 ratio is reported to decrease with age and disease status in infants (75) that could partly explain the decrease of DNA damage biomarkers at 6 months relative to birth in the present cohort. Future studies could investigate this possibility using 'sorted cell microarrays' that have been developed to score MN in different lymphocyte subsets (53) . The mean (± SD) for NDI observed in cord blood in our cohort was 1.5 (± 0.16) and is similar to that reported by Vande-Loock et al. (1.59 ± 0.20, n = 182,) in cord blood collected from a Greek cohort (37) . Another mother-infant cohort study, investigating the impact of the intrauterine environment on health risks in adult life, observed a similar mean NDI (1.57 ± 0.12: n = 92) (34), suggesting that differences in DNA damage biomarkers between cohort could not be explained by differences in cell culture conditions or replication stress factors. Our study also found strong inverse association between CBMN-Cyt biomarkers and NDI implying that DNA damage leading to NPB and NBUD formation causes DNA replication stress and cell cycle delay (45, (76) (77) (78) (79) (80) (81) and that these effects may initiate in utero (82) .
We found significant correlation between frequency of apoptotic lymphocytes and DNA damage biomarkers (MN, NPB, NBUD) at 3 months but not with NDI in our study. The lymphocytes in cord blood spontaneously apoptose to a greater degree when compared with adult peripheral blood ex vivo (83, 84) . The majority of neonatal lymphocytes have a naive phenotype (85) that may indicate their Each DNA damage biomarker was tested for Gaussian distribution and then Pearson 'r' (parametric test for normal distribution data) and Spearman 'r' was calculated (non-parametric test for non-Gaussian distribution). MN and NBUD are presented per 1000 BNCs, MN and NBUD are presented per 100 MNC, N: number of subjects.
Significant at ****P ≤ 0.0001; ***P ≤ 0.01; **P ≤ 0.05. functional immaturity with regard to proliferative response to mitogens and antigens (86) . It is possible that the frequency of apoptotic lymphocytes of neonates were immature T lymphocytes that were using programmed cell death mechanisms to prevent further mutations/MN in daughter nuclei (87) .
Association of infant birth outcomes with mother's anthropometric variables and CBMN-Cyt biomarkers
We found gestation age of infants to be correlated positively with MN and NPB but negatively with NDI. The previous observations have been contradictory with this regard; where studies did not find any effect of gestation age on MNBNC in cord blood in a Serbian cohort (88) and in a Greek cohort (34) . The positive association of MN and NPB with gestation age are not easy to interpret with respect to biological significance or mechanism. However, a positive association of MN, NPB and NBUD with infant birth weight and of NPB and NBUD with birth length and negative association of birth head circumference with apoptotic lymphocytes suggest that a larger infant size may be consequential to more DNA damage possibly due to relaxation of cell cycle checkpoints to allow cell division and tissue growth. Further, a recent longitudinal cohort study also observed that obese infants (with BMI ≥ 95th) at birth and at 6 months of age had shorter telomere length at 4-6 years age compared to non obese infants (P = 0.004 and P = 0.048, respectively) (89) . Shorter telomere length leading to telomere end fusion is usually associated with more MN, NPB and NBUD, particularly with NPB which is the biomarker for telomere dysfunction/shortening (45) . We also observed that NPB measured in infants at birth increased significantly with mother's weight and BMI suggesting the possibility of an effect related to metabolic processes that promote a higher BMI (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) . In this regard, we checked the association of maternal anthropometry data with infant birth outcome and found significant positive correlation of mother's height with infant birth weight ( Tables 5). The positive correlations of maternal weight and gestation age with infant's weight and length at birth and their association with increased DNA damage further supports the possibility of trans-generational metabolic programming (94, 95, (101) (102) (103) (104) (105) (106) . This is supported by recent findings of a prospective Boston-Birth cohort study where childhood z scores for BMI was observed to be positively associated with maternal pre-pregnancy BMI. The risk of childhood overweight or obesity (measured at 6 years of age) was significantly increased in overweight [RR = 1.3 (95% CI: 1.2, 1.6)] and obese [RR=1.6 (95% CI: 1.3, 1.8)] mothers' children compared to the risk of childhood overweight and obesity in children of normal-weight mothers (based on maternal pre-pregnancy BMI). Additionally, the risk of childhood overweight increased significantly by 30% with each unit increase in maternal pre pregnancy BMI [RR = 1.3 (95% CI: 1.1, 1.4)] (29). We also observed that mother's BMI was negatively associated with APGAR scores assessed at 5 min after birth. The positive association of APGAR score with NDI and negative correlation with NPB suggests a beneficial impact of improved cell division and lower chromosomal instability in immune system cells during very early stages of life after birth. The biological relevance and mechanism of association are difficult to explain unless a higher NDI and lower NPB happen to be indicators of stress resistance given the high metabolic stress of the birthing process (107) (108) (109) . Hence, the novel findings of an association of infant birth outcomes with CBMN biomarkers needs further investigation in a larger cohort along with adjustments for intra and/or extra-uterine factors given the recent data on the possibility of epigenetic effect of in utero exposures on MN frequency in lymphocytes of mothers and neonates shown through association of women's environment including diet (26, 33, 110) and air pollutants (29, 32) during pregnancy.
One of the limitations of the study was that our samples were drawn from a small cohort and some correlations were weak that may not adequately represent the entire population. Furthermore, it is to be noted that, out of 794 eligible women, only 115 consented which indicates a difficulty in recruitment which may possibly lead to bias in relation to the study outcomes. In addition, a further limitation is that only mothers with low risk of pregnancy complications were recruited so that the data may not represent those with higher risk of DNA damage given that a high MN frequency at 18 weeks gestation was predictive of risk for pre-eclampsia or intrauterine growth restriction (111) . Further we did not measure DNA damage in the subtypes of lymphocytes which might have allowed more accurate comparison of CBMN-Cyt biomarkers obtained for the cord blood relative to those lymphocytes collected at 3 and 6 months after birth.
In conclusion, to our knowledge, this is the first study to have compiled baseline data for DNA damage among neonates of healthy women in South Australia using the CBMN-Cyt assay. This data provides a useful baseline reference to assist in the design of further studies aimed at monitoring changes in DNA damage in the human life cycle, caused by exposure to environmental genotoxin, poor lifestyle and malnutrition. The study shows significant positive associations of infant birth outcomes (gestation age, birth length and birth weight) with DNA damage biomarkers that suggests the possibility of a genotoxic effect on infant's DNA by metabolic processes that promote increase growth and higher BMI of infants.
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